Deep Cyclic Inhibition of MEK in RAS-Mutant Tumors: Constraining MAPK-Axis Escape and Preserving Combination Optionality

• The emerging resistance landscape for chronic RAS inhibition, including recurrent MAPK-axis reactivation mechanisms
• The rationale for deep cyclic MEK inhibition as an alternative evolutionary pressure model
• Clinical ctDNA evidence from atebimetinib-treated RAS-mutant tumors, including PDAC
• How this profile may support combination strategies with mutant-selective RAS inhibitors, RAF inhibitors, chemotherapy, immunotherapy, RTK-directed agents, or radiotherapy 

Speakers:

Praveen Nair

Vice President of Translational Pharmacology

Immuneering Corp.